Cardiology

Lilly reports dose-dependent PCSK9 and LDL-C reductions with single-dose VERVE-102 in interim phase 1b hypercholesterolemia data.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

FDA granted priority review to asundexian for secondary prevention after non-cardioembolic ischemic stroke or TIA.

FDA approved baxdrostat as add-on therapy for adults with hypertension not controlled on other medications.

Stay updated with the latest healthcare breakthroughs, including FDA submissions and new cardiology guidelines.

Lucas Boersma, MD, PhD, discusses the 1-year results of the Enlighten study, highlighting effective defibrillation, low rate of complications, and high ATP success.

Mehdi Shishehbor, DO, PhD, discusses the 6-month results from his recent study, confirming the efficacy of the LimFlow System in patients with CLTI.

Erin Ferranti, PhD, MPH, discusses the new guidelines and their implications for continued enhancement of both access to and outcomes of postpartum care.

Sameh Sayfo, MD, discusses his recent analysis of the DETOUR2 study, highlighting the efficacy of the DETOUR system for patients regardless of runoff.

Bilchick discusses his recent study, highlighting a reduced risk of atrial fibrillation in patients taking prescription GLP-1 RAs irrespective of weight loss.

Saseen discusses the current dyslipidemia treatment landscape, highlighting current challenges and potential paths forward.

Stay updated with the latest healthcare breakthroughs, including data from DDW and a new podcast episode.

Ahmad Masri, MD, from OHSU, discusses the positive topline results from this phase 3 trial, highlighting a new path forward for nHCM.

Patient education may be the missing piece needed to bridge the gap between hypertension treatments and improved outcomes.

Hear Andrew Sauer, MD, discuss how he broke through mental health challenges to become one of the leading voices in transplant cardiology.

Blaha discusses his study analyzing nonstatin prescriptions from 2019-2024, highlighting the need for further clinical implementation of modern guidelines.

April 2026 saw further updates from ACC.26, plus key trial results, guideline updates, and more.

Lu explains findings that link PCBP1 to the pathogenesis of AARS2-related cardiomyopathy.

The FDA granted Fast Track Designation to coramitug, an investigational anti-TTR antibody designed to clear existing amyloid deposits in ATTR cardiomyopathy.

Kass explains recent findings from a study that suggest myocardial dysfunction in HFpEF may be reversible with weight loss.

Kass explains 2 distinct biological subgroups discovered in HFpEF and how they relate to a paradigm shift.

Propensity-matched data link empagliflozin to lower risk of CV events, AKI, and other outcomes versus dapagliflozin in type 2 diabetes.

Shoamanesh discusses the positive data from OCEANIC-STROKE, a phase 3 trial comparing the investigative FXIa inhibitor to placebo in patients with prior ischemic stroke.

Patel provides an inside perspective on one of the most diagnostically challenging cardiovascular conditions.